Trevi Therapeutics (TRVI) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Join SI Premium – FREE
Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
